Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified versus standard Myfortic dosing after de novo kidney transplantation
2006-003633-32Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium in kidney transplant immunosuppression (2 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Oct 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2006-003633-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003633-32.